NDA 217806 · Eli Lilly and CO
Zepbound
Tirzepatide · Subcutaneous · Glucose-dependent Insulinotropic Polypeptide Receptor Agonist; GLP-1 Receptor Agonist
NovelBreakthrough therapyPriority reviewLast checked: Nov 20, 2026Latest source record: Aug 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Nov 8, 2023
Approved uses
4
Original approval plus efficacy supplements
Registered trials
242
59 Phase 3, 94 recruiting
FAERS reports
84,243
7,972 serious, 225 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ) and Nonclinical Toxicology ( 13.1 )]. ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of ZEPBOUND and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid...
What it is approved for
From the label in effect Aug 28, 2026.
ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. ( 1 ) Limitations of Use: Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. ( 1 ) Limitations of Use ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.
Mechanism: Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. GLP-1 is a physiological regulator of appetite and caloric intake. Nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake. Both GIP receptors and GLP-1 receptors are found in areas of the brain involved in appetite regulation. Animal studies show that tirzepatide distributes to and...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 26, 2026 Supplement 41 · Efficacy LetterLabel
- Dec 20, 2024 Supplement 13 · Efficacy · priority review Breakthrough therapyLabelMedication GuideLetter
- Oct 18, 2024 Supplement 6 · Efficacy LetterLabel
- Nov 8, 2023 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated · priority review NovelLabelLetterReview
24 products under this application
- ZEPBOUND · TIRZEPATIDE 60MG/2.4ML (25MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND KWIKPEN · TIRZEPATIDE 60MG/2.4ML (25MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND · TIRZEPATIDE 40MG/2.4ML (16.7MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND · TIRZEPATIDE 5MG/0.5ML (5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND KWIKPEN · TIRZEPATIDE 40MG/2.4ML (16.7MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND · TIRZEPATIDE 20MG/2.4ML (8.33MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND (AUTOINJECTOR) · TIRZEPATIDE 15MG/0.5ML (15MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND KWIKPEN · TIRZEPATIDE 20MG/2.4ML (8.33MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND · TIRZEPATIDE 15MG/0.5ML (15MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND (AUTOINJECTOR) · TIRZEPATIDE 10MG/0.5ML (10MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND · TIRZEPATIDE 10MG/0.5ML (10MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND (AUTOINJECTOR) · TIRZEPATIDE 5MG/0.5ML (5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND KWIKPEN · TIRZEPATIDE 10MG/2.4ML (4.17MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND · TIRZEPATIDE 50MG/2.4ML (20.8MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND · TIRZEPATIDE 7.5MG/0.5ML (7.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND KWIKPEN · TIRZEPATIDE 50MG/2.4ML (20.8MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND · TIRZEPATIDE 30MG/2.4ML (12.5MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND · TIRZEPATIDE 2.5MG/0.5ML (2.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND KWIKPEN · TIRZEPATIDE 30MG/2.4ML (12.5MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND · TIRZEPATIDE 10MG/2.4ML (4.17MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND (AUTOINJECTOR) · TIRZEPATIDE 12.5MG/0.5ML (12.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND · TIRZEPATIDE 12.5MG/0.5ML (12.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND (AUTOINJECTOR) · TIRZEPATIDE 7.5MG/0.5ML (7.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZEPBOUND (AUTOINJECTOR) · TIRZEPATIDE 2.5MG/0.5ML (2.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tirzepatide" as an intervention, any sponsor and status, largest first.
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05556512 · 15,374 participants · Start Oct 11, 2022 · Primary completion Oct 2027
Drug: Tirzepatide; Placebo · For: Obesity; Overweight
Sites: Gilbert, Arizona; Mesa, Arizona; Phoenix, Arizona · 672 sites in all
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT04255433 · 13,299 participants · Start May 29, 2020 · Primary completion Jun 12, 2025
Drug: Tirzepatide; Dulaglutide · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Concord, California; Covina, California · 635 sites in all
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07165028 · 4,500 participants (planned) · Start Oct 15, 2025 · Primary completion Aug 2030
Drug: Tirzepatide; Retatrutide and 1 more · For: Metabolic Dysfunction-Associated Steatotic Liver Disease
Sites: Tuscaloosa, Alabama; Chandler, Arizona; Gilbert, Arizona · 563 sites in all
- A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07247084 · 3,000 participants (planned) · Start Nov 24, 2025 · Primary completion Jul 2029
Drug: Tirzepatide · For: Obesity
Sites: Altrincham, United Kingdom; Ashton-under-Lyne, United Kingdom; Bolton, United Kingdom · 30 sites in all
- Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)Pivotal-lookingRecruiting
Hudson BiotechIndustry
NCT07481747 · 2,539 participants (planned) · Start Feb 2, 2026 · Primary completion Feb 14, 2027
Drug: Tirzepatide; Placebo · For: Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Sites: Shenzhen, China
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or OverweightPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT04184622 · 2,539 participants · Start Dec 4, 2019 · Primary completion Apr 1, 2022
Drug: Tirzepatide; Placebo · For: Overweight; Obesity
Sites: Pelham, Alabama; Scottsdale, Arizona; Concord, California · 118 sites in all
- A Study of EloraTZP in Adult Participants With Obesity Without Type 2 DiabetesPivotal-lookingNot yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07881432 · 2,115 participants (planned) · Start Dec 2026 · Primary completion Oct 2029
Drug: eloralintide and tirzepatide; Eloralintide and 2 more · For: Obesity
Sites: Mesa, Arizona; Scottsdale, Arizona; Tucson, Arizona · 161 sites in all
- A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular RiskPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03730662 · 2,002 participants · Start Nov 20, 2018 · Primary completion Jan 22, 2021
Drug: Tirzepatide; Insulin Glargine · For: Type 2 Diabetes Mellitus
Sites: Anaheim, California; Covina, California; Greenbrae, California · 216 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- incorrect dose administered14,801
- nausea9,989
- drug ineffective5,679
- diarrhoea5,254
- injection site pain5,171
- extra dose administered5,050
- vomiting4,257
- constipation3,882
- fatigue3,138
- accidental underdose2,613
- injection site erythema2,451
- weight increased2,430
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 6 |
| 2020 | 3 |
| 2021 | 13 |
| 2022 | 35 |
| 2023 | 119 |
| 2024 | 11,202 |
| 2025 | 32,100 |
| 2026 | 40,761 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zepbound (Tirzepatide)
2024 spending
$387K
Beneficiaries
245
353 claims
Per beneficiary
$1,581
$509.13 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $387,343 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Rosenstock J, Wysham C, Frías JP, et al. · Lancet 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Aronne LJ, Horn DB, le Roux CW, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Comparative Study
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
Yao H, Zhang A, Li D, et al. · BMJ 2024 · Systematic Review, Network Meta-Analysis
- Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.
Zhao L, Cheng Z, Lu Y, et al. · JAMA 2024 · Clinical Trial, Phase III, Multicenter Study
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
Malhotra A, Grunstein RR, Fietze I, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
Aronne LJ, Sattar N, Horn DB, et al. · JAMA 2024 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Eli Lilly · Also marketed as Zepbound Kwikpen, Zepbound (Autoinjector)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.